The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.259 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
OBJECTIVE: To characterize rates of regional Alzheimer disease (AD)-specific brain atrophy across the presymptomatic, mild cognitive impairment, and dementia stages. DESIGN: Multicenter case-control study of neuroimaging, cerebrospinal fluid, and cognitive test score data from the Alzheimer's Disease Neuroimaging Initiative. SETTING: Research centers across the United States and Canada. PATIENTS: We examined a total of 317 participants with baseline cerebrospinal fluid biomarker measurements and 3 T1-weighted magnetic resonance images obtained within 1 year. MAIN OUTCOME MEASURES: We used automated tools to compute annual longitudinal atrophy in the hippocampus and cortical regions targeted in AD. We used Mini-Mental State Examination scores as a measure of cognitive performance. We performed a cross-subject analysis of atrophy rates and acceleration on individuals with an AD-like cerebrospinal fluid molecular profile. RESULTS: In presymptomatic individuals harboring indicators of AD, baseline thickness in AD-vulnerable cortical regions was significantly reduced compared with that of healthy control individuals, but baseline hippocampal volume was not. Across the clinical spectrum, rates of AD-specific cortical thinning increased with decreasing cognitive performance before peaking at approximately the Mini-Mental State Examination score of 21, beyond which rates of thinning started to decline. Annual rates of hippocampal volume loss showed a continuously increasing pattern with decreasing cognitive performance as low as the Mini-Mental State Examination score of 15. Analysis of the second derivative of imaging measurements revealed that AD-specific cortical thinning exhibited early acceleration followed by deceleration. Conversely, hippocampal volume loss exhibited positive acceleration across all study participants. CONCLUSIONS: Alzheimer disease-specific cortical thinning and hippocampal volume loss are consistent with a sigmoidal pattern, with an acceleration phase during the early stages of the disease. Clinical trials should carefully consider the nonlinear behavior of these AD biomarkers.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Archives of Neurology
- Topic
- Dementia and Cognitive Impairment Research
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Avid RadiopharmaceuticalsGenentechNational Institutes of HealthNational Institute of Biomedical Imaging and BioengineeringUniversity of California, Los AngelesIpsenTel Aviv UniversityEisaiBayer HealthCareMultiple Sclerosis SocietyKorean Neurological AssociationNorthern California Institute for Research and EducationMcGill UniversityNational Institute of Neurological Disorders and StrokeUniversity of PittsburghU.S. Social Security AdministrationJohns Hopkins UniversityAssistance publique-Hôpitaux de ParisHarvard CatalystSynarcMedpaceEllison Medical FoundationWashington University in St. LouisGlaxoSmithKlineBristol-Myers SquibbU.S. Department of DefenseEli Lilly and CompanyAstraZenecaMontreal Neurological Institute and HospitalElanHarvard UniversityNational Center for Research ResourcesF. Hoffmann-La RocheYork UniversityPfizerAlzheimer's AssociationSPIENational Center for Complementary and Integrative HealthNational Institute on AgingAbbott LaboratoriesUniversity of California, San DiegoU.S. Department of Veterans Affairs
- Keywords
- Alzheimer's Disease Neuroimaging InitiativeAtrophyNeuroimagingHippocampal formationDementiaHippocampusBrain sizeMagnetic resonance imagingAlzheimer's diseasePsychologyNeuroscienceMedicineCerebrospinal fluidCognitionInternal medicineEffects of sleep deprivation on cognitive performanceDiseaseRadiology
- Has abstract in OpenAlex
- yes